Literature DB >> 1640530

The pharmacokinetics of intravesical and oral oxybutynin chloride.

C A Massad1, B A Kogan, F E Trigo-Rocha.   

Abstract

In 8 children with cystometric evidence of bladder instability and marked systemic side effects to oral oxybutynin we investigated the efficacy of intravesical instillation and compared the pharmacokinetics of both routes of delivery. In addition, 4 healthy dogs underwent intravesical instillation for pharmacokinetic studies. Intravesical oxybutynin was well tolerated, efficacious and rapidly absorbed, resulting in plasma concentrations markedly higher than after oral administration. In only 2 patients did this method of instillation result in side effects, and both had previously undergone bladder augmentation. This lack of significant systemic side effects despite high plasma concentrations suggests that a metabolite may be generated after oral administration that is responsible for the side effects. These studies demonstrate that the mode of administration affects the mechanism of action, side effects, pharmacokinetics and metabolism of oxybutynin, and that intravesical instillation is clinically effective and results in minimal side effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1640530     DOI: 10.1016/s0022-5347(17)36663-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  22 in total

Review 1.  [Intravesical treatment of overactive bladder syndrome].

Authors:  A Haferkamp; M Hohenfellner
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

2.  Transdermal systems for overactive bladder: principles and practice.

Authors:  David R Staskin
Journal:  Rev Urol       Date:  2003

3.  Management of overactive bladder with transdermal oxybutynin.

Authors:  Jonathan S Starkman; Roger R Dmochowski
Journal:  Rev Urol       Date:  2006

Review 4.  Overactive bladder in children.

Authors:  Sophie Ramsay; Stéphane Bolduc
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

5.  [Intravesical therapy for overactive bladder].

Authors:  J Pannek; U Grigoleit; R Wormland; M Goepel
Journal:  Urologe A       Date:  2006-02       Impact factor: 0.639

Review 6.  Intravesical drug delivery. Pharmacokinetic and clinical considerations.

Authors:  M S Highley; A T van Oosterom; R A Maes; E A De Bruijn
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

7.  Intravesical oxybutinin chloride in children with intermittent catheterization: sonographic findings.

Authors:  J M Zerin; M A DiPietro; M L Ritchey; D A Bloom
Journal:  Pediatr Radiol       Date:  1994

8.  A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder.

Authors:  Michael J Kennelly
Journal:  Rev Urol       Date:  2010

9.  The evolution of transdermal therapy for overactive bladder.

Authors:  Peter K Sand
Journal:  Curr Urol Rep       Date:  2009-09       Impact factor: 3.092

10.  Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination.

Authors:  Karen May; Thomas Giessmann; Danilo Wegner; Reinhard Oertel; Christiane Modess; Stefan Oswald; Manfred Braeter; Werner Siegmund
Journal:  Eur J Clin Pharmacol       Date:  2008-07-15       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.